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OUTCOME OF ALLOGENEIC (ALLO) STEM CELL TRANSPLANT (SCT)
AFTER FAILURE OF A PRIOR SCT: A SINGLE CENTER’S EXPERIENCE
Alluri, K.C., Paba, C.E., Nath, R.Methodist University Hospital/Univer-
sity of Tennessee Cancer Institute, Memphis, TN
Introduction: SCT is a curative option for patients with hemato-
logical malignancies.Treatment options for patients who relapse
after a prior SCT are limited and often not curative. There is little
experience of allo-SCT in this setting because of concerns of trans-
plant related mortality.
Methodology: Retrospective review was performed of all pa-
tients who received an allo-SCT at Methodist University Hospital
between february 2003 and february 2008 after failing a prior SCT.
There were 12 (7 males, 5 females) patients. The median age was
45.5 range (25–75) years at the time of allo-SCT. Primary diagnosis
included lymphoma -5 (4 non-hodgkin,1 hodgkin), acute leukemia
-3 and multiple myeloma (MM) - 4. Median number of prior ther-
apies was 4 range (2–7). Prior SCT was autologous (auto) in 10 pa-
tients (1 patient-3 autoSCT; 1 patient-2 autoSCT) and allogeneic
in 2. Eight patients had active disease and 4 were in complete remis-
sion (CR) prior to their allo-SCT. Four patients (all with MM) had
developed a secondary MDS/AML prior to their allo-SCT. SCT
co-morbidity index was $ 3 in 8 and #2 in 4 patients. Median
time from a previous SCT to allo-SCT was 11.6 range (8.6–75.3)
months. Donor was a matched sibling for 8 and unrelated donor
for 4 patients. Preparative regimen was Fludarabine(F) /Melphalan
(140mg/m2) 6 antithymocyte globulin (ATG) 6 Rituxan (R) in 8,
F/cytoxan 6 ATG6 R in 3 and Melphalan (200mg/m2) in one pa-
tient. Graft versus host disease prophylaxis was tacrolimus/metho-
trexate in 10 patients and cyclosporine/ mycophenolate mofetil in 2
patients. All 11 evaluable patients engrafted with a median time to
neutrophil engraftment of 11 range (10–16) days and a median time
to platelet engraftment of 19 range (9–37) days. Nine patients
achieved a CR and 2 had persistent disease after the allo-SCT.
Seven patients died at a median of 151 range (7–524) days post
allo SCT: 5 from tranplant related mortality (TRM) and 2 from
progressive disease. Five patients are alive and disease free at
9,16, 25,42 and 66 months post allo-SCT. Two patients are off
all immunosuppressive therapy.
Conclusion: Allo-SCT after failure of a prior SCT is feasible and
can result in prolonged survival.317
STABLE MIXED DONOR-DONOR CHIMERISM AFTER DOUBLE CORD
BLOOD TRANSPLANTATION
Gertow, J., Berglund, S., Okas, M., Ringden, O., Uhlin, M., Mattsson, J.
Karolinska University Hospital, Huddinge, Stockholm, Sweden
Umbilical cord blood is increasingly used as a source of stem cells
in allogeneic stem cell transplantation due to it’s naı¨ve cell content
and high permissiveness forHLA-mismatch. To overcome problems
of limited cell numbers, double cord blood transplantation (DCBT)
has proven both safe and efficacious. Concerning chimerism analysis
after DCBT, previous studies have indicated single unit predomi-
nance early after DCBT. In the present study we evaluated the chi-
meric pattern in T-, B- and myeloid cells using PCR based
chimerism analysis in patients after DCBT. Of the seven patients
included in this study, five had acute leukemia and two patients
had lymphoma. Five patients received myeloablative conditioning
and two patients were given reduced intensity conditioning. Interest-
ingly, three patients showed mixed donor chimerism in all cell line-
ages at 100 days post-transplantation, and two of them still at 25 and
29 months after DCBT, respectively. These two patients are doing
clinically well, with no infectious complications or signs of relapse,
and neither of them developed acute GVHD after DCBT. All
patients received high dose antithymocyte globulin (ATG) before
DCBT, which could be an explanation for an increased tolerance
between the cord blood units. Immunological studies revealed phe-
notypic differences between the two cord blood units. Among other
things, antigen presenting cells and T cells of memory phenotype
predominated in one cord blood unit, whereas natural killer cells
were found in higher frequencies in the other unit. In conclusion,
in this study donor-donor mixed chimerism was common after
high dose ATG and DCBT, and in these cases phenotypical114differences between the two cord blood units regarding memory
phenotype were found.GVH/GVL318
TARGETING OF HLA CLASS II RESTRICTED ANTIGENS IN GRAFT VERSUS
LEUKEMIA REACTIVITY
Falkenburg, J.H.F., Stumpf, A., Rutten, C.E., van der Meijden, E.D.,
Luxemburg-Heijs, S.A.P., van Bergen, C.A.M., Willemze, R.,
Griffioen, M. Leiden University Medical Center, Leiden, Netherlands
The beneficial effect of allogeneic HLA matched stem cell trans-
plantation (SCT) can be attributed toT cells recognizingminor histo-
compatibility antigens (mHag) expressed on hematopoietic cells of
recipient origin. T cells recognizing HLA class I restricted mHag se-
lectively expressed on hematopoietic cells have been shown to be capa-
ble of inducing Graft versus Leukemia/lymphoma (GVL) reactivity
without significant Graft versus Host Disease (GVHD). Since HLA
class II is predominantly expressed on hematopoietic cells, we charac-
terized the role of HLA class II directed T cell responses in GVL re-
activity. Since the HLA class II locus consists on HLA-DR, HLA-
DQandHLA-DPwe identifiedwhether all different class IImolecules
could be involved in GVL reactivity. First, we identified the role of
CD4Tcells in a patient successfully treatedwithdonor lymphocyte in-
fusion (DLI) for relapsed leukemia after HLA matched SCT who
experienced only mild GVHD of the skin. 5 HLA class II restricted
mHag were molecularly identified including a HLA-DQ restricted
mHag were encoded by PI4K2B, and four HLA-DR restricted
mHag. These newly identified autosomal HLA-DR restricted mHag
wereencodedbyaNADP1dependentdehydrogenasegene (restricted
byDRB1*0301), aC-type lectin receptorgene (DRB1*1301), a protein
tyrosine kinase gene (DRB3*0101), and a non-classical MHC class I
gene (DRB3*0202). These genes show selective or predominant ex-
pression in cells of hematopoietic origin and the immunogenic variants
havebalancedpopulation frequencies of 25–70%.AllT cell clones rec-
ognized high HLA class II-expressing patient-derived B-cells, mature
dendritic cells and in vitro cultured leukemic cells with antigen-pre-
senting phenotype. From a patient with a B cell leukemia successfully
treatedwithDLI resulting inGVLreactivitywithoutGVHDwe iden-
tified an exclusive T cell response targeting only HLA-DP expressed
on hematopoietic cells of recipient origen. We demonstrated that in
the absence of inflammatory cytokines none of the HLA class II re-
stricted T cells recognized non-hematopoietic cells. Only after pro-
found upregulation of HLA class II on non-hematopoietic cells,
some of the T cell clones could recognize non-hematopoietic tissues.
In conclusion, we demonstrate thatHLAclass II restricted alloreactive
Tcells contribute toGVLreactivity in the absenceofGVHD,andmay
be sufficient to elicit anti-tumor reactivity in HLA class II expressing
hematological malignancies.319
PREVENTION OF ACUTE GVHD DURING HAPLO-BMT: EVALUATING THE
EFFICACY OF T-CELL COSTIMULATION BLOCKADE USING A NOVEL RHE-
SUS MACAQUE TRANSPLANT MODEL
Miller, W.P.1, Wheeler, C.E.1, Panoskaltsis-Mortari, A.2, Kirk, A.D.1,
Larsen, C.P.1, Blazar, B.R.2, Kean, L.S.1 1Emory University, Atlanta,
GA; 2University of Minnesota, Minneapolis, MN
Wehave developed a fully pedigreed andMHC-typed Rhesus ma-
caque BMT model, with which to study GvHD and its prevention.
For the current study, we have concentrated on MHC haplo-identi-
cal BMT, and determined the effect of T cell costimulation blockade
on GvHD prophylaxis. Our preparative regimen consists of TBI (8
Gy with lung shielding to 6 Gy). GvHD is graded using standard
clinical grading scales. Here we report on the first experimental co-
hort. The first animal served as a control for TBI-based preparation,
and, as expected exhibited profound pancytopenia. The second ani-
mal was transplanted with haploidentical hematopoietic stem cells
(4.47  108 total nucleated cells/kg and 1.10  108 CD31 T cells/
kg) and was treated with only rapamycin for immunosuppression.
He exhibited profuse diarrhea and necrotic skin changes within 8
days of transplant, coincident with early engraftment, and was sacri-
ficed at day 14. A diagnosis of Grade IV skin GvHDwas rendered on
